surmount trials tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide

Its recommended to increase the dose gradually (every four weeks) if additional blood sugar management is needed

A better understanding of the intersecting pathophysiology of HFpEF and AF reveals therapeutic targets that can address both conditions

Leave behind ineffective solutions and let our DNA testing and hormone analysis uncover any hidden culprits

Convenience: With online consultations and chat support, you can get care when you need it without long wait times or office visits

Dose Conversion Tirzepatide Dose and Units Calculator Convert a prescribed dose into medication volume and syringe units using the selected concentration

Necessary cookies are always active